Clinical Trials Logo

Clinical Trial Summary

This open-label, multi-cohorts, phase 1/2 study has the primary objective of comparing decitabine-primed tandem CART 19/20 solo, with decitabine-primed tandem CART 19/20 plus chidamide, decitabine-primed tandem CART 19/20 plus decitabine, and decitabine-primed tandem CART 19/20 plus decitabine+chidamide in patients with aggressive B-NHL who were confirmed as Relapsed and/or Refractory B cell Non-Hodgkin's Lymphoma with hugh tumor burden (Sum of the Product of the perpendicular Diameters for multiple lesions, SPD ≥ 100cm^2 or the largest-diameter of tumor ≥ 10 cm.).

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

  • Aggression
  • Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden

NCT number NCT04553393
Study type Interventional
Source Chinese PLA General Hospital
Contact Weidong Han, M.D.
Phone +861055499341
Status Recruiting
Phase Phase 1/Phase 2
Start date September 9, 2020
Completion date September 8, 2022